Accès ouvert

Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages

Article scientifique 2022 Anglais

Résumé

Abstract The SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VOC) and its sub-lineages (including BA.2, BA.4, BA.5, BA.2.12.1) contain spike mutations that confer high level resistance to neutralizing antibodies. The NVX-CoV2373 vaccine, a protein nanoparticle vaccine, has value in countries with constrained cold-chain requirements. Here we report neutralizing titers following two or three doses of NVX-CoV2373. We show that after two doses, Omicron sub-lineages BA.1 and BA.4/BA.5 were resistant to neutralization by 72% (21/29) and 59% (17/29) of samples. However, after a third dose of NVX-CoV2373, we observed high titers against Omicron BA.1 (GMT: 1,197) and BA.4/BA.5 (GMT: 582), with responses similar in magnitude to those triggered by three doses of an mRNA vaccine.These data are of particular relevance as BA.4/BA.5 is dominating in multiple locations, and highlight the potential utility of the NVX-CoV2373 vaccine as a booster in resource-limited environments.

Citer ce document

Bhiman, J., Richardson, S., Lambson, B., Kgagudi, P., Mzindle, N., Kaldine, H., Crowther, C., Gray, G., Bekker, L., Shinde, V., Bennett, C., Glenn, G., Madhi, S., Moore, P., Koen, A., Fairlie, L., Fouche, L., Bhorat, Q., Dheda, K., Tameris, M., Masilela, M., Hoosain, Z., Singh, N., Hanley, S., Archary, M., Louw, C., Grobbelaar, C., Lalloo, U., Joseph, N., Kruger, G. (2022). Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages. https://doi.org/10.21203/rs.3.rs-2048259/v1

Accès au document

Voir sur le dépôt source

Ce document est hébergé sur son dépôt institutionnel d'origine.

Statistiques

Consultations : 1

Téléchargements : 0